Saving lives by defeating ARDS from any cause

Learn more

ARDS (Acute Respiratory Distress Syndrome) is a severe, life-threatening medical condition characterized by widespread inflammation and fluid accumulation in the lungs. Every year, this condition kills more people than breast and prostate cancer combined. With no approved pharmacotherapy and caused by pneumonia, sepsis and trauma, this is a huge unmet medical need.

Exvastat has created the first stable formulation of imatinib, Impentri™, that can be delivered intravenously. This hugely extends its value as it can be used with patients unable to receive oral treatments due to coma. This aspect transforms our ability to prevent the tragic loss of human life due to ARDS.

Read more
Icon1
Intravenous therapy
perfect for critical care
Icon2
Can be administered
without delay
Icon3
Not blocked by
mechanical ventilation
Icon4
Does not rely on
GI tract absorption
Connection

Our story

In 2008, a woman with life-threatening pulmonary oedema was treated in an Amsterdam hospital…

She was resistant to all the normal therapeutic options, and treated off-label with imatinib, a drug then thought promising for pulmonary hypertension…

The oedema disappeared within 24 hours, leading to the hypothesis that the same drug could be effective in similar conditions, like Acute Respiratory Distress Syndrome (ARDS).

This has now been confirmed in a Phase II proof-of-concept study.

Read more

Partner with us to save lives

Contact us

About Impentri™

Impentri™ is a high impact product that is uniformly effective in a heterogeneous condition. The new treatment is based on the drug's ability to inhibit vascular leak, which drives the pulmonary oedema. It has proven effective in a number of human case reports as well as in vivo models.

ARDS currently lacks any approved pharmaceutical therapy, with treatment limited to supportive ventilatory care. As Impentri™ can significantly reduce the high mortality and incapacitating morbidities caused by ARDS, it will radically reduce the cost of care.

Read more

Latest News

Jun 21, 2021

CounterCOVID study shows imatinib significantly reduces mortality by 49% in patients with COVID-19

Results published on Friday 18th June by Exvastat’s collaborator in The Lancet Respiratory Medicine show that oral imatinib, currently used to treat cancers, reduces mortality by 49% in hospitalized COVID-19 patients. The results of the world-first trial, led by VUmc, Amsterdam, could signify another option in the management of COVID-19 to protect lives

Read more

May 18, 2021

Exvastat commence work on EU grant awarded to initiate Phase II trial of IV imatinib for the treatment of COVID-19 pneumonia

18th May 2021: Cambridge, UK, Exvastat Limited, is pleased to announce it has commenced work on a prestigious European Innovation Council (EIC) accelerator grant, to support development of its innovative treatment, Impentri™ (intravenous imatinib) for the treatment of Acute Respiratory Distress Syndrome (ARDS) related to COVID-19.

Read more

Apr 26, 2021

Appointment of Dr Julian Gilbert as Non-Executive Director

Read more
All news News page photo